Stability of extemporaneously prepared rifaximin oral suspensions. 2010

Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
Department of Clinical Sciences, College of Pharmacy, University of Michigan Hospitals and Health Centers, 1500 East Medical Center Drive, Ann Arbor, MI 48105-5247, USA. mcober@umich.edu

OBJECTIVE The stability of extemporaneously prepared rifaximin oral suspensions was studied. METHODS An oral suspension of rifaximin 20 mg/mL was prepared by thoroughly grinding six 200-mg tablets of rifaximin in a glass mortar. Thirty milliliters of Ora-Plus and 30 mL of either Ora-Sweet or Ora-Sweet SF were mixed and added to the powder to make a final volume of 60 mL. Three identical samples of each formulation were prepared and placed in 2-oz amber plastic bottles with child-resistant caps and were stored at room temperature (23-25 degrees C). A 1-mL sample was withdrawn from each of the six bottles with a micropipette immediately after preparation and at 7, 15, 30, and 60 days. After further dilution to an expected concentration of 20 microg/mL with mobile phase, the samples were assayed in duplicate using stability-indicating high-performance liquid chromatography. The samples were visually examined for any color change and pH was tested on each day of analysis. Stability was determined by evaluating the percentage of the initial concentration remaining at each time point and defined as retention of at least 90% of the initial concentration of rifaximin. RESULTS At least 99% of the initial rifaximin remained throughout the 60-day study period in both preparations. There were no detectable changes in color, odor, taste, or pH and no visible microbial growth in any sample. CONCLUSIONS Extemporaneously prepared suspensions of rifaximin 20 mg/mL in 1:1 mixtures of Ora-Plus with either Ora-Sweet or Ora-Sweet SF were stable for at least 60 days when stored in 2-oz amber plastic bottles at room temperature.

UI MeSH Term Description Entries
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D004356 Drug Storage The process of keeping pharmaceutical products in an appropriate location. Drug Storages,Storage, Drug,Storages, Drug
D000078262 Rifaximin A synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of GASTROENTERITIS caused by ESCHERICHIA COLI INFECTIONS. It may also be used in the treatment of HEPATIC ENCEPHALOPATHY. 4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin,L 105,L-105,Redactiv,Xifaxan,L105
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D012294 Rifamycins A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei. Rifamycin,Rifomycin,Rifomycins
D013535 Suspensions Colloids with liquid continuous phase and solid dispersed phase; the term is used loosely also for solid-in-gas (AEROSOLS) and other colloidal systems; water-insoluble drugs may be given as suspensions. Suspension

Related Publications

Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
May 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
March 2010, The Annals of pharmacotherapy,
Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
April 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
January 2017, International journal of pharmaceutical compounding,
Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
July 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
January 2020, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG,
Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
December 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
January 2006, International journal of pharmaceutical compounding,
Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
June 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Mary Petrea Cober, and Cary E Johnson, and Jordan Lee, and Kenne Currie
October 2017, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Copied contents to your clipboard!